Search for: "Astrazeneca" Results 241 - 260 of 1,244
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Apr 2019, 10:09 pm
The deal will see two pharma giants collaborate to commercialise a new treatment for specific types of cancer. [read post]
11 Apr 2019, 10:59 am by Camilla Hrdy
He discussed it further on several posts on Sufficient Description, leading up to the Supreme Court of Canada's decision to abolish the doctrine in AstraZeneca Canada Inc. v. [read post]
8 Apr 2019, 9:59 pm by Patent Docs
" 2018 sales were up for all reported companies except Gilead, AstraZeneca, and Teva, and the change in rankings generally had more to do with competitors' improvements (and increased sales) than reductions in sales 2018 to 2017. [read post]
15 Mar 2019, 9:47 am by Sander van Rijnswou
This opposition appeal provides a very interesting application of the problem-solution approach to a pharmaceutical formulation. [read post]
5 Mar 2019, 9:38 am by Patrick A. Malone
Media reports of the Senate Finance hearing called it “political theater,” and it offered lawmakers a chance to vent at execs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer, and Sanofi. [read post]
1 Mar 2019, 12:25 am by Boukje van der Maazen
As the prior art encourages the skilled person to do research to find other suitable calcimimetic molecules, the skilled person would not be discouraged by the size and extent of the research (contrary to the above referred to Sandoz/AstraZeneca case where such a pointer was lacking). [read post]
5 Feb 2019, 7:34 am by Lindsay Offutt
Chairman Chuck Grassley and Ranking Member Ron Wyden sent the invitations to AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer and Sanofi. [read post]
5 Feb 2019, 1:19 am by Philipp Widera
Philipp WideraAstraZeneca tried to enjoin Hexal from marketing its Fulvestrant-medicament in main proceedings (after already having failed in PI-proceedings) due to alleged patent infringement of AstraZeneca’s Swiss-type claim patent. [read post]
23 Jan 2019, 5:36 am
Originally the District Court invalidated AstraZeneca’s patents due to lack of an inventive step. [read post]
8 Jan 2019, 4:09 am by Bart van Wezenbeek
Bart van WezenbeekFor establishing inventive step it is not necessary that the prior art contains a pointer for combination, only that in the relevant prior art an incentive was present to combine the prior art. [read post]
1 Nov 2018, 6:26 am by Robert Kraft
The warning applies to the class of SGLT2 inhibitors, specifically, Johnson & Johnson’s Invokana (canagliflozin), AstraZeneca Plc’s Farxiga (dapagliflozin), and Eli Lilly & Co. [read post]
20 Sep 2018, 5:31 pm by Sarah Ralph and Rebekah French
The Fair Work Commission reached a similar decision again this year in Australian Workers’ Union, The v AstraZeneca Pty Ltd [2018] FWC 4660 when it was asked to rule on how personal/carer’s leave is to be calculated for shiftworkers at pharmaceutical company, AstraZeneca Pty Ltd. [read post]
11 Sep 2018, 12:50 pm by Anders Valentin
Consequently, the Danish Maritime and Commercial Court held that AstraZeneca had neither rendered probable or proven that it was the proprietor of an exclusive right that could be infringed, and so the application for interim relief was turned down. [read post]
20 Aug 2018, 1:25 pm by Tim Curtis
Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in financing and a promise of creating 100 jobs within five years. [read post]
17 Aug 2018, 12:40 pm by ncharles
  The disclosures by Pfizer, AstraZeneca, Roche, and Johnson & Johnson came in their quarterly SEC filings. [read post]
9 Aug 2018, 3:55 pm by luiza
AstraZeneca previously settled charges of other federal and state Medicaid fraud schemes in 2015. [read post]
31 Jul 2018, 5:29 am by Joe Patrice
[Courthouse News Service] * If you're an armed terrorist organization, AstraZeneca may be able to help. [read post]
29 Jun 2018, 2:35 pm
ASTRAZENECA – SUPREME COURT Eelco Bergsma reports in the "EPLAW" Blog on this case which dealt with whether the description of the patent provided for a limiting definition of the claim.DesignsMoving on to some design news, the blog Marques reported that the Hague System expands to UK. [read post]